Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

Original reporting
Published Nov 2, 2026, 12:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RGEN
Bullish
high confidence
Mentioned
$RGEN
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RGENBullishMed
01

Why it matters

The earnings beat and higher price target provide a fresh catalyst that could attract buying interest.

02

Market read

The new earnings data and analyst target may drive short‑term price appreciation for RGEN.

03

What to watch

Margin and cost synergies from the Biolife acquisition are still uncertain and could affect future performance.

Relevance 7/10Novelty 7/10Timing: post-market reaction

Background

Repligen reported record Q3 2026 revenue and earnings, driven by its Chromatography and Proteins segments, while Stifel reaffirmed its Buy stance.

Company-level read

Ticker impact

$RGENBullishHigh confidence
Context

Stifel reiterated a Buy rating on Repligen, kept a $207 price target and highlighted strong Q3 2026 earnings that beat expectations.

Expected impact

likely upward pressure as investors price in the earnings beat and higher target.

Evidence & confidence

The earnings beat and higher price target are fresh facts that can move the stock in the near term.

Market effects

Strong results may lift the broader biotech and life‑science tools sector.

Positive for US‑listed biotech stocks.

Limited to investors tracking US biotech equities.

Counterpoint

Some analysts remain cautious, maintaining a Hold rating despite the earnings beat.

Key entities

  • Repligen Corporation

    Biotech company reporting earnings and receiving analyst coverage.

  • Stifel

    Equity research firm reiterating a Buy rating and $207 target.

Related articles

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.